ASA TABLET (DELAYED-RELEASE)
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
30-05-2022
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
ACETYLSALICYLIC ACID
Tillgänglig från:
PHARMASCIENCE INC
ATC-kod:
B01AC06
INN (International namn):
ACETYLSALICYLIC ACID
Dos:
81MG
Läkemedelsform:
TABLET (DELAYED-RELEASE)
Sammansättning:
ACETYLSALICYLIC ACID 81MG
Administreringssätt:
ORAL
Enheter i paketet:
24/30/100/120/150/180/225/250/255/1000
Receptbelagda typ:
OTC
Terapiområde:
SALICYLATES
Produktsammanfattning:
Active ingredient group (AIG) number: 0101169013; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2014-11-20
Produktens egenskaper
PRODUCT MONOGRAPH
ASA
Acetylsalicylic Acid Delayed-release Tablets USP
81 mg
Platelet aggregation inhibitor
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
DATE OF REVISION:
May 30, 2022
www.pharmascience.com
SUBMISSION CONTROL NUMBER: 263622
_Product Monograph - ASA _
_ _
_ _
_ _
_Page 2 of 39 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................9
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................12
SPECIAL HANDLING INSTRUCTIONS
.......................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II : SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................14
CLINICAL TRIALS
....................................................
Läs hela dokumentet
